Marcus Davidsson, PhD
Founder & COO
Prior to founding rAAVen Therapeutics, Marcus spent the last decade on DNA barcoding and AAV engineering. Marcus started his work at Lund University, where he developed novel DNA barcoding methods for AAV engineering and gene therapy. Beside this, he has also
worked extensively on generating DNA libraries, how to sequence DNA libraries and enhancer-promoter optimization.
He holds a PhD in Neuroscience from Lund University and has postdoc experience from Michigan State University in Grand Rapids, MI and Barrow Neurological Institute in Phoenix, AZ.
Patrick Aldrin-Kirk, PhD
Patrick joined rAAVen as CSO in 2022 following more than a decade of academic research. He holds a PhD within neurobiology with a focus on the use of engineered AAV vectors, using these to elucidate changes in both disease conditions and during treatment. He was part of the original rAAVen research team that developed the screening platform now in use by rAAVen therapeutics. Patrick continued his scientific career as a postdoc at Copenhagen university, Denmark, which was followed by a position as assistant professor before joining rAAVen Therapeutics.